Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease. Issue 1 (3rd August 2017)

• Record Type: Journal Article
• Authors: Greish, Khaled; Taha, Safa; Jasim, Anfal; Elghany, Sara Abd; Sultan, Ameera; AlKhateeb, Ali; Othman, Manal; Jun, Fang; Taurin, Sebastien; Bakhiet, Moiz
• Is Part Of: Clinical and translational medicine. Volume 6:Issue 1(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-08-03
• Subjects: Styrene maleic acid (SMA) -- Raloxifene -- Inflammatory bowel disease (IBD) -- Nanomedicine -- Enhanced permeability and retention effect (EPR) -- Inflammatory cytokines; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-017-0157-2
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Inflammatory bowel disease (IBD) comprises a group of disorders that manifest through chronic inflammation of the colon and small intestine. Although the exact cause of IBD is still unclear, dysfunctional immunoregulation involving overproduction of inflammatory cytokines such as TNF‐α, and IL‐6 have been implicated in pathogenesis. Current therapy relies on immunosuppression, cytotoxic drugs, and monoclonal antibodies against TNF‐α. These classes of drugs have severe side‐effects, especially when used for long duration. Our previous work with raloxifene, a selective estrogen receptor modulator, has shown that the drug, and to a greater extent its micellar formulation, has a significant suppressive effect on NF‐κB, an essential immune‐regulator. This finding directed the current work towards testing the anti‐inflammatory and immunomodulatory effects of raloxifene using cell lines, as well as testing the potential use of the styrene maleic acid (SMA) micelles loaded with raloxifene (SMA‐Ral) against dextran sulfate sodium (DSS) induced colitis in an in vivo model of IBD. Results: Treatment of MCF‐7 cells with TNF‐α was shown to protect the cells from the cytotoxic effect of raloxifene (42 vs. 10% cell death, with TNF‐α. Treating CaCo‐2 cells with both free and SMA‐Ral improved cell survival after exposure to 2% DDS with significantly higher protection with SMA‐Ral. Treatment of U‐937 with SMA‐Ral and free‐Ral resulted in down‐regulation of TNF‐α, IL‐1β, IL‐6, and MIP1α, with greater inhibition of the SMA‐Ral, compared to free Ral. Balb/c mice treated with raloxifene and SMA‐Ral showed weight gain at 14 days, compared to the control group (122, and 115% respectively). Treatment with raloxifene prevented DSS‐induced diarrhea in 6/6 of free raloxifene treated mice and in 5/6 mice treated with SMA‐Ral. Control group of DSS‐treated mice showed average colon length of 7.4 cm compared to 13 cm in the control group. The average colon length was 12.3 and 11.5 cm for raloxifene and SMA‐Ral treated groups, respectively. Furthermore, inflammatory cytokines such as IL‐6 and TNF‐α were reduced in serum of animals treated with free‐Ral and SMA‐Ral. Conclusions: Raloxifene and its micellar formulation warrants further studies to understand their effect on the treatment of colitis. Abstract : SMA‐Raloxifene preparation and its in vivo and in vitro effect on colitis